Prochainement en français

En attendant tu peux continuer à naviguer dans la version anglaise.




Endometrial Receptivity Analysis

Evaluates the status of the woman’s endometrial receptivity to prevent implantation failure

Scroll Down


  • ERA is a diagnostic test patented by IGENOMIX in 2009 that helps to evaluate the woman’s endometrial receptivity.
  • ERA identifies a patient’s unique “window of implantation” (WOI) leading to a personalized embryo transfer (pET).
  • 3 in every 10 patients have a displaced WOI. In such cases, a second endometrial biopsy is needed to identify when the patient is receptive.

More info


An endometrium is receptive when it is ready for embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is what we call the window of implantation.

This is why it is recommended to assess the endometrium in order to determine the optimal day for embryo transfer.

The ERA test requires an endometrial biopsy that should be carried out on day LH+7 (natural cycle) or day P+5 (HRT cycle). This biopsy is quickly and easily taken by a gynecologist in their consultation room and sent to Igenomix for testing.
The ERA test analyzes the expression levels of 248 genes linked to the status of endometrial receptivity, using RNA sequencing taken from the endometrial tissue.

3 in every 10 patients have a displaced WOI. The ERA is able to predict receptivity and recommend a transfer within a 24hr shift in the WOI.


The Endometrial Receptivity Analysis (ERA®) has been designed, developed and patented by IGENOMIX (PCT/ES2009/000386).


  • ERA identifies the window of implantation (WOI) and recommends the best time for embryo transfer thereby increasing the chances of a successful outcome.
  • The ERA test has proven highly sensitive and accurate in detecting gene expression profiles associated with endometrial receptivity.
  • The ERA test resulted in a 73% pregnancy rate in patients with implantation failure.

Ruiz-Alonso et al, Fertil Steril. 2013
Clemente-Ciscar et al, 2018, submitted


    • Women who have experienced implantation failures with morphologically good quality embryos.
    • Women with a morphologically normal uterus and normal endometrial thickness (≥ 6 mm), where the uterus and endometrium are unlikely to be the problem.



The ERA test is performed with Next Generation Sequencing (NGS) technology

  • NGS is a scalable technology allowing large numbers of samples to be analyzed simultaneously.
  • NGS flexibility and accuracy has enabled the development of a new, improved predictor tool and will allow us to further enhance the test's effectiveness and include additional diagnostic markers.

More Info



Scientific publications and documents

ERA publications

ERA publications

Other scientific documents

Other scientific documents

Our results

We are proud to deliver high quality results for every test, every day. Our experts are professional, reliable and approachable and are available to help guide both professionals and patients throughout the entire process.

More than


ERA tests performed



More than




scientific publications

Become our provider

We will help you get started quickly and efficiently


Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

Newsletter subscription